Fraunhofer ITEM: High-Performance-Center Translational Medical Engineering
Together with representatives from industry, government and academia, Dr. Gabriele Heinen-Kljajić, Minister for Science and Culture of Lower Saxony, and Prof. Reimund Neugebauer, President of the Fraunhofer-Gesellschaft inaugurated the High-Performance Center Translational Biomedical Engineering in Hannover on April 25.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170425006452/en/
The Center is aimed at bringing medical devices from the lab into phase I of clinical development. The focus is on active implants and technological solutions for inhaled drug delivery. The latter are systematically developed towards smart-drug/device combination products. The Center is funded by the Lower-Saxony government and the Fraunhofer-Gesellschaft. “Be it research on and development of implants, regenerative or personalized medicine – we want to contribute to overcoming the difficult step of transferring medical research results into clinical application, so that patients can benefit from novel products and methods. The new High-Performance Center Translational Biomedical Engineering provides a valuable link between research institutions and industry. It further strengthens the close network of research in the life sciences in Hannover,” said Heinen-Kljajić.
“In this Center, we will assist researchers, companies and entrepreneurs from the very phase of development. Dedicated manufacturing processes, for example, commonly represent substantial economic hurdles for small and medium-sized enterprises. Furthermore, medical devices equally have to go through quality assurance and risk assessment processes, before they can progress to clinical trials. We guide through the sophisticated processes of bringing devices from basic research to clinical application,” said Prof. Theodor Doll, head of the Center. Doll is holding a professorship instituted at the Hannover Medical School in collaboration with Fraunhofer ITEM . It directly connects the research done in the clusters of excellence REBIRTH and “Hearing4all ” in Hannover and in the Lower-Saxony consortium “Biofabrication for NIFE ” with the Fraunhofer ITEM translation expertise.
“Within a very short time, the High-Performance Centers of the Fraunhofer-Gesellschaft have proven to excellently support cooperation with universities and industry. The aim is to broadly promote research and education, training and continuing professional development, career opportunities for both young and senior scientists, and the transfer from lab to fab. The High-Performance Centers shall be established as infrastructure for this transfer,” explained Neugebauer. “The new Translational Biomedical Engineering Center provides optimal opportunities to step into a top position in innovative medical device development. Together with our partners, we can provide decisive impetus for future innovations to industry, SMEs and start-ups in the medical sector.”
Further information: https://www.item.fraunhofer.de/en/press-and-media/press-releases/PM_center_inauguration.html .
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
GA-AGCO19.10.2017 16:32 | pressemeddelelse
AGCO Announces a New Data Connection with The Climate Corporation’s Climate FieldViewTM Digital Agriculture Platform
TIRENDO-HOLDING-GMBH19.10.2017 16:27 | pressemeddelelse
Arrive Safely: Head to Tirendo and Equip Yourself Properly for Your First Winter
EURID19.10.2017 15:50 | pressemeddelelse
EURid Reveals the Nominees for The 2017 .eu Web Awards
CA-ANDERSEN-TAX19.10.2017 15:32 | pressemeddelelse
Andersen Tax Launches in Canada
IL-UL19.10.2017 14:02 | pressemeddelelse
UL Joins Sustainable Apparel Coalition
NJ-CELGENE19.10.2017 13:32 | pressemeddelelse
Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum